Table 2.
Summary Donor and Transplantation Variables Distribution Split by MICA Matched versus MICA Mismatched within 10/10 and 9/10 HLA Matching
| Variable | MICA Matched | MICA Mismatched | P Value* |
|---|---|---|---|
| High-resolution HLA matches available out of 10 | <.001 | ||
| 9/10 (mismatch at HLA-B) | 54 (10) | 107 (56) | |
| 10/10 | 468 (90) | 84 (44) | |
| Graft type | .12 | ||
| Marrow | 139 (27) | 40 (21) | |
| PBSC | 383 (73) | 151 (79) | |
| Conditioning regimen | .68 | ||
| Myeloablative | 359 (69) | 140 (73) | |
| RIC | 115 (22) | 37 (19) | |
| Nonmyeloablative | 29 (6) | 9 (5) | |
| Other | 19 (4) | 5 (3) | |
| Donor age at donation, yr | .05 | ||
| 10–19 | 17 (3) | 7 (4) | |
| 20–29 | 184 (35) | 52 (27) | |
| 30–39 | 174 (33) | 57 (30) | |
| 40–49 | 110 (21) | 53 (28) | |
| ≥ 50 | 37 (7) | 22 (12) | |
| Median (range) | 33 (18–61) | 37 (19–60) | .003 |
| Donor/recipient CMV serostatus | .92 | ||
| Negative/negative | 144 (28) | 58 (30) | |
| Negative/positive | 180 (34) | 63 (33) | |
| Positive/negative | 56 (11) | 19 (10) | |
| Positive/positive | 130 (25) | 48 (25) | |
| Unknown | 12 (2) | 3 (2) | |
| GVHD Prophylaxis | .45 | ||
| Tacrolimus + MMF ± others | 96 (18) | 26 (14) | |
| Tacrolimus + MTX ± others (except MMF) | 303 (58) | 117 (61) | |
| CSA + MMF ± others (except tacrolimus) | 42 (8) | 14 (7) | |
| CSA + MTX ± others (except tacrolimus, MMF) | 81 (16) | 34 (18) | |
| Donor/recipient sex match | .74 | ||
| Male/male | 191 (37) | 72 (38) | |
| Male/female | 155 (30) | 49 (26) | |
| Female/male | 83 (16) | 32 (17) | |
| Female/female | 93 (18) | 38 (20) | |
| Year of transplantation | .88 | ||
| 2000 | 10 (2) | 2 (1) | |
| 2001 | 8 (2) | 6 (3) | |
| 2002 | 17 (3) | 5 (3) | |
| 2003 | 34 (7) | 9 (5) | |
| 2004 | 36 (7) | 16 (8) | |
| 2005 | 67 (13) | 30 (16) | |
| 2006 | 71 (14) | 25 (13) | |
| 2007 | 77 (15) | 29 (15) | |
| 2008 | 67 (13) | 25 (13) | |
| 2009 | 66 (13) | 18 (9) | |
| 2010 | 43 (8) | 16 (8) | |
| 2011 | 26 (5) | 10 (5) | |
| Follow-up among survivors, mo | |||
| No. evaluated | 215 | 68 | |
| Median (range) | 51.2 (3.3–147.6) | 60.7 (11.8–119.8) | .09 |
PBSC indicates peripheral blood stem cells, RIC, reduced-intensity conditioning; CMV, cytomegalovirus; MMF, mycophenolate mofetil; MTX, methotrexate; CSA, cyclosporin A.
*
The Pearson chi-square test was used for comparing discrete variables; the Kruskal-Wallis test was used for comparing continuous variables.